Erectile dysfunction (ED) is a very common problem, and is thought to affect 30-45% of 40-70 year old men to some degree. A common cause of erectile dysfunction is reduced blood flow in the penis, called vasculogenic ED.
ED1000 is a new treatment option for erectile dysfunction, which aims to improve blood flow in the penis and cure erectile dysfunction, enabling the patient to achieve and maintain dependable erections.
ED1000 is a new treatment and aims to bring lasting improvements in erectile function without medication
Vijay Sangar Consultant Urologist
How does it work?
ED1000 shockwave therapy involves low-intensity shockwaves, similar to ultrasound waves, which are focused onto the treatment area, stimulating the treated tissues to grow new micro blood vessels. Research suggests that the improved micro vessel network increases the blood supply to the erectile tissue, resulting in improved erection quality.
How effective is ED1000?
Early results indicate that treatment improves the quality of erections in three out of four patients with vasculogenic ED or diabetes. In one research study* 77% of men with early ED, who were responding to medication, were cured, achieving spontaneous erections and intercourse.
In another study** 70% of men with severe ED, who were not responding to 5-phosphodiesterase inhibitors, started to respond to medication after ED1000 treatment, returning to a sex life with the help of 5-phosphodiesterase inhibitor tablets. They were able to discontinue more cumbersome or invasive treatments such as vacuum pumps or injection therapy.
Who will benefit from ED1000?
Patients with vasculogenic ED or diabetes are the best candidates for ED1000 treatment. There are currently no published studies on using ED1000 for impotence due to other causes, such as prostate surgery, trauma, Peyronie's disease or Parkinson's. However, some men may have a combination of poor penile blood flow and another cause for their ED and it is possible they may still benefit from the treatment.
What is vasculogenic ED?
Poor penile blood flow is a common reason for erectile dysfunction and presents in 70% of men with organic (non-psychological) ED. Some patients may already have a diagnosis of vascular problems, such as previous heart attack or stroke. Many others may have risk factors for vascular disease, including high blood pressure, high cholesterol and history of smoking, that make vasculogenic ED more likely.
What does the treatment involve?
A thorough assessment of the patient, including physical examinations, screening and counselling, will be required prior to treatment. If the patient is felt to be suitable, ED1000 is given as an out-patient treatment in a series of 12 short treatment sessions over nine weeks – twice weekly during weeks one to three, followed by a break of three weeks and then a further three weeks of twice weekly treatments.
The initial treatment will usually be given by the consultant and subsequent treatments by a fully trained nurse. There will usually be two consultant follow-up visits, one during and one after treatment has been completed. Following the treatment, longer-term routine follow-up is offered.
Are there any side effects?
ED1000 is a non-invasive and entirely pain-free treatment that does not require any additional medication. A gentle tapping sensation may be felt during the treatment. To date there are no reported side-effects during or after the treatment and the treatment is considered to be safe. Patients are able to return to their daily routines immediately following each treatment session.
What are the longer term outcomes from ED1000?
Early evidence shows that results have been maintained for up to two years after treatment. This is the longest follow-up currently available.
How is shockwave therapy different from other ED treatments?
Other ED treatments involving medication carry the risk of side effects, work only during a set time window, often require a degree of planning of sexual activity and incur ongoing drug costs.
Shockwave therapy is a non-invasive, non-pharmacological therapy which aims to trigger a natural mechanism that improves penile blood flow and may allow restoration of penile function and sexual spontaneity without need for ongoing treatment.
*Presented at the 26th Annual European Association of Urology Congress, Vienna, March 2011.
**Presented at the 13th Congress of the European Society for Sexual Medicine, Malaga, November 2010.